WO2006001364A1 - ヒトパピローマウイルス疾患治療薬および抗ヒト免疫不全ウイルス薬 - Google Patents
ヒトパピローマウイルス疾患治療薬および抗ヒト免疫不全ウイルス薬 Download PDFInfo
- Publication number
- WO2006001364A1 WO2006001364A1 PCT/JP2005/011600 JP2005011600W WO2006001364A1 WO 2006001364 A1 WO2006001364 A1 WO 2006001364A1 JP 2005011600 W JP2005011600 W JP 2005011600W WO 2006001364 A1 WO2006001364 A1 WO 2006001364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lignin
- active ingredient
- polymer
- main active
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- the present invention relates to a human papillomavirus disease therapeutic agent, and a phenylpropenoid, which is an extract mainly composed of lignin and lignin-like polysaccharide, and mainly contains a component called pinosol or pureanol.
- the present invention relates to a therapeutic drug for human papillomavirus disease and an anti-human immunodeficiency virus drug, which mainly comprises a synthetic polymer obtained by dehydrogenation polymerization.
- the present inventors examined the effectiveness of the extract obtained from pine strength especially for other viral diseases, and found that it has a very excellent therapeutic effect on human papillomavirus disease! I started out.
- Patent Document 1 Japanese Patent Laid-Open No. 3-206043
- Patent Document 2 JP-A-1-238532
- Patent Document 3 JP-A-1-238533
- Patent Document 4 Japanese Patent Laid-Open No. 1-6218
- Patent Document 5 JP-A-64-4601
- Patent Document 6 Japanese Patent Laid-Open No. 62-205032
- the subject of the present invention is obtained by dehydration polymerization of human papillomavirus disease drugs and phenolic propenoids, which mainly contain an extract containing lignin and lignin-like polysaccharide as main components.
- the object is to provide a therapeutic agent for human papillomavirus disease and an anti-human immunodeficiency virus agent comprising a synthetic polymer as a main active ingredient.
- an extract containing lignin and a capita-like polysaccharide as a main component obtained by hot water extraction or aqueous alkaline solution extraction of pine cones (hereinafter referred to as "lignin-like extract”). ) Is a therapeutic agent for human papillomavirus disease.
- the present invention provides a synthetic polymer obtained by dehydrogenation polymerization of a fuel propenoid represented by the following formula (1) (hereinafter referred to as "polymer [I]").
- the main active ingredient is human papilloma, a therapeutic agent for mavirus disease.
- R 1 represents a hydroxyl group or a methoxy group
- n is an integer of 1 to 5
- one or more of R 1 is a hydroxyl group
- R 2 represents a carboxyl group, a hydroxymethyl group or a methoxy group.
- a carboxyl group is shown.
- “human papillomavirus” is expressed as “HPV”.
- the present invention provides an anti-human immunodeficiency virus drug comprising the polymer [I] as a main active ingredient.
- HIV human immunodeficiency virus
- the lignin-like extract which is the main active ingredient of one therapeutic agent for HPV disease of the present invention, is obtained by hot water extraction of pine cone or alkaline aqueous solution extraction, and contains lignin and lignin-like polysaccharide.
- the pine strength used as the raw material for the lignin-like extract is not particularly limited, and various pine strengths such as black pine, red pine, and five leaf pine can be used.
- the extraction of pine cones is performed with hot water or an aqueous alkaline solution.
- the lignin-like extract of the present invention comprises components eluted by hot water extraction, components eluted by alkaline aqueous extraction, and hot water. Any of the components eluted by further extracting the residue after extraction with an aqueous alkaline solution, or a mixture of any two or more of these components may be used.
- the hot water extract contains oil, since this oil contains medicinal ingredients, both non-oil and oil may be administered together when taken orally.
- Extraction of pine cones with hot water can be performed in accordance with, for example, the methods described in Patent Document 5 and Patent Document 6, and after washing the pine cone as a raw material with cold water or slightly warm water as necessary. Alternatively, it is performed by degreasing and removing low molecular weight substances by washing with alcohol, followed by boiling or roasting in hot water for a certain period of time, and performing these under reflux.
- the processing conditions such as the amount and temperature of hot water used, the number of extractions, the processing temperature, and the processing time are appropriately selected according to the harvest time, drying state, and amount of pine force used as the raw material. can do.
- each extract may be administered individually, or two or more extracts may be administered together, but the first extract alone and those containing the extract are preferred.
- the obtained hot water extract After the obtained hot water extract is cooled to room temperature, it can be administered orally or by injection as it is or after adjusting the concentration.
- the extract after cooling can be administered by filtering with a gauze, filter paper or the like. If the extract contains oil, the oil may be removed using a separatory funnel, for example.
- the active ingredient contained in the hot water extract can be fractionated as follows, and each fraction can be administered alone or in admixture of two or more.
- the hot water extract is filtered to remove insolubles, the filtrate is concentrated under reduced pressure, ethanol (EtOH) is added, and the resulting precipitate is collected by filtration. Then, the precipitate is dissolved in distilled water, and the resulting aqueous solution is dialyzed against distilled water and then treated with a DE AE cellulose column (C1-type) equilibrated with distilled water. Obtain I and adsorbed fraction. The adsorbed fraction was then eluted with 0.5M aqueous sodium chloride solution, 2M aqueous sodium chloride solution or 0.15M aqueous sodium hydroxide solution to give Fr.II, Fr.III and (Fr.IV + Fr.V, respectively). ) Each fraction.
- Fr.V was further removed by gel filtration with 0.15N sodium hydroxide aqueous solution using Sepharose CL-4B. (Molecular weight range 1 to 70,000) and Fr.V-2 (molecular weight range 70 to 200,000).
- the pine strength extraction treatment with an alkaline aqueous solution can be performed in accordance with, for example, the method described in Patent Document 5, and after washing the pine cone as a raw material with cold water or slightly warm water as necessary, or After degreasing and removing low-molecular substances by washing with alcohol, the residue treated directly or by hot water extraction as described above is extracted with an aqueous alkaline solution.
- the concentration of the aqueous alkaline solution used for the aqueous alkaline solution extraction can be selected as appropriate, but it is preferably not so high because the pH is adjusted to weak acidity in the subsequent step.
- the processing conditions such as the amount of alkaline aqueous solution used, the number of extractions, the processing temperature, the processing time, etc. depend on the harvest time and drying state of the raw material, pine force, the amount of pine force used, the amount of hot water extraction residue, etc. According Can be selected as appropriate.
- the extract solution after extraction with alkaline aqueous solution is centrifuged or filtered to separate the precipitate fraction Fr.VI, and then the pH is adjusted to usually 4-6, preferably around 5, with acetic acid, carbonic acid, etc. The Then, add 1 volume of ethanol (EtOH) (EtOH) to the aqueous phase and mix, mix the resulting precipitate, for example by centrifugation or filtration, and separate the precipitate fraction Fr.VII. Separate the precipitate fraction Fr.VIII and the precipitate fraction Fr.IX by treating in the same manner with 2 volumes of ethanol (EtOH) or 5 volumes of ethanol (EtOH). Then, each precipitate fraction is dialyzed against distilled water and lyophilized.
- the amount of ethanol used is not limited to that described above, but can be selected as appropriate.
- the alkali of the alkaline aqueous solution used in the alkaline aqueous solution extraction treatment may be an inorganic alkali or an organic alkali, but is preferably sodium hydroxide (NaOH) or potassium hydroxide. Further, instead of ethanol added to the aqueous phase, other alcohols may be used.
- Figure 1 shows the flow of operations for performing alkaline aqueous solution extraction on the residue after hot water extraction, together with the yield (number in parentheses, unit: wt%) for each fraction.
- the polymer [I] of the present invention is obtained by dehydrogenation polymerization of the fullerpenoids represented by the above formula (1) (hereinafter referred to as “farpropenoids (1)”). It is obtained.
- the phenol derivative (1) has a structure in which a monovalent or polyvalent phenol or a derivative thereof has a structure in which a straight carbon chain having 3 carbon atoms having ⁇ and ⁇ double bonds is bonded.
- 2-Propene derivative has a structure in which a monovalent or polyvalent phenol or a derivative thereof has a structure in which a straight carbon chain having 3 carbon atoms having ⁇ and ⁇ double bonds is bonded.
- the phenol derivative (1) has a cis type and a trans type depending on the configuration of the substituent R 2 , but the trans type is stable, and the trans type is usually used as a raw material for polymer particles.
- the phenol derivative (1) has optical activity as a single molecule and exists as a levorotatory or dextrorotatory optical isomer. However, when an equal amount of both optical isomers are mixed, a racemic compound is obtained. Become a body. Any of these optical isomers and racemates can be used as the raw material for the polymer and polymer particles in the present invention.
- phenol derivative (1) a compound in which a hydroxyl group is present in a position para to the group —CH ⁇ CH—R 2 is particularly preferable.
- Specific examples of the preferred phenol derivative (1) in the present invention include the following formula (1-1):
- the compound represented by-(17) can be mentioned.
- the polymer [I] is prepared, for example, in accordance with the method described in Non-Patent Document 1, with at least one of the phenol derivatives (1) having a pH of generally 6 to 9, preferably 6 to Dehydrogenation polymerization in an aqueous solution of 8, preferably in a buffered aqueous solution such as sodium phosphate buffer solution in the presence of a peroxide such as peroxyhydrogen and a dehydrogenase such as peroxidase. It can be synthesized from what you do.
- each reaction raw material can be mixed and reacted by an appropriate method.
- an aqueous solution of the phenol derivative (1) and the peroxide is dehydrated.
- examples thereof include a method of adding an enzyme solution into an aqueous solution, and a method of adding an aqueous solution of a peroxide into an aqueous solution of a phenol derivative (1) and a dehydrogenase.
- the polymer [I] after dehydrogenation polymerization is a polymer [I] obtained from an acidic phenol derivative (1) such as trans-p-tamaric acid.
- the pH is generally 5 or less, preferably 4 or less, so that the polymer [I] can be precipitated and then recovered by filtration, centrifugation, etc., and can be recovered by neutrality such as trans-p-cumyl alcohol.
- the reaction solution is adjusted to PH3 with acetic acid and concentrated under reduced pressure, and then the residue is dissolved in ethanol. The solution can be recovered by, for example, concentrating the solution under reduced pressure.
- the polymer [I] typically has a structure in which structural units represented by the following formula [i] (hereinafter referred to as "structural units [i]”) are linked. .
- R 3 represents a hydroxyl group or a methoxy group
- m is an integer of 0 to 4
- Z is represented by the following formula [a]
- R 1 represents a hydroxyl group or a methoxy group, and n is an integer of 0 to 4.
- [0037] represents a unit bonded to an oxygen atom at the position of a carbon atom with an arrow ( ⁇ ).
- R 2 represents a carboxyl group, a hydroxymethyl group or a methoxycarbon group, and the structural unit represented by the formula [i] adjacent in the polymer molecular chain is linked between two bonds marked with *. ing. ]
- the polymer [I] in order to increase the water solubility of the polymer [I], it can be used by binding mannose or daricans.
- the average molecular weight of the polymer [I] is usually 1,000 to 200,000, preferably 1,000 to 50,000.
- the polymer [I] is caused by HPV diseases such as plantar use (warts), vulgaris use, flat-use use, eclampsia, endometriosis, and eclampsia, and HIV. It acts effectively on cases and is extremely useful as a therapeutic agent for these diseases or cases.
- HPV diseases such as plantar use (warts), vulgaris use, flat-use use, eclampsia, endometriosis, and eclampsia, and HIV. It acts effectively on cases and is extremely useful as a therapeutic agent for these diseases or cases.
- the polymer [I] has a structure similar to that of natural lignin and directly affects the virus. Expected to suppress the intracellular synthesis of abnormal proteins that are thought to cause autoimmune diseases or suppress the growth of cancer cells by binding and inactivating the virus or activating immunity It can be done.
- HPV disease therapeutic drug to be divided is not to administer each fraction obtained by the extraction process described above alone, or to apply it, or to administer any two or more fractions in combination. Apply it.
- HPV disease therapeutic agent and a polymer containing a lignin-like extract as a main active ingredient and a polymer [I] as a main active ingredient are administered and not administered as an HPV disease therapeutic agent.
- oral administration of powder or solution, application of ointment, injection of solution, etc. may be employed.
- an anti-HIV drug containing the polymer [I] as a main active ingredient oral administration of powder or solution, injection of solution, etc. can be employed as an aspect of administering or applying an anti-HIV drug containing the polymer [I] as a main active ingredient. can be employed.
- lignin-like extract or polymer [I] When a lignin-like extract or polymer [I] is used as a powder, generally the smaller the particle size, the less absorbed the body and the less the resistance when taken orally. Lignin-like extracts and polymers [I] are not only facilitated by penetration into the skin, absorption into cells, and absorption, but also facilitate preparation of ointments and solutions. It is possible to promote absorption into the body by breaking down the molecular chain and reducing the molecular weight.
- a pulverizer such as a ball mill or a rod mill, enzyme treatment, etc. can be employed.
- the medium of the solution used for oral administration and injection for example, water, physiological saline, or a mixture thereof can be used.
- HPV disease drugs and anti-HIV drugs are supplemented with auxiliary medicinal ingredients such as polysaccharides and vitamins that are effective in enhancing immunity to improve or adjust their medicinal effects, or seasoning ingredients such as licorice and herbs. Can be added to facilitate oral administration.
- the Fr. VI and Fr. VII granules shown in Figure 1 are encapsulated in gelatin capsules, and this is lignin-like extract 1 to 3 times a day.
- 20 mgZ day of oral administration was continuously taken orally.
- 47 days after the start of administration no progression of cancer was observed and the progression was la.
- the egg Surgery was performed to remove the uterus while leaving the nest, and no cancer cells were found in the affected area.
- the lignin-like extract is effective as a therapeutic agent for eclampsia cancer caused by HPV.
- fractions Fr. VI and Fr. VII shown in Fig. 1 patients No. 1 to 9 and 16 to 25 in Table 1 were mixed with an aqueous solution dissolved in pure water to obtain a fraction concentration of 5 ⁇ 10 wt.% Ointment was prepared, and this ointment was applied to the patient's diseased sites shown in Table 1 2-3 times a day.
- the same fractions Fr.VI and Fr.VII 3 mg per capsule was encapsulated in gelatin capsules, and this was administered orally once to 6 times a day, and the lignin-like extract dose was 3 to 18 mg Z days.
- excellent treatment effect was confirmed except for the progression of some patients. This therapeutic effect on HPV disease was not seen with other conventional treatments, both for ointment application and oral administration.
- “Period” in the “Treatment Results” section means the treatment period from the time of first visit.
- This polymer [I] has a molecular weight of less than 10,000, 52% by weight, a molecular weight of 10,000 to 30,000, less than 00, 27% by weight and a molecular weight of 30,000 or more to 21% by weight, and an average molecular weight of 14 , 300 and IR, NMR and UV were as follows:
- polymer [la] This polymer [I] is referred to as “polymer [la]”.
- solution A and solution B were mixed, and 65 liters of solution C was added dropwise over 1 hour with stirring, then acetic acid was added to adjust the solution to pH 3 and cooled in the refrigerator for 1 hour. .
- the resulting suspension is treated with a 6, OOOrpm centrifuge to collect the precipitate, washed twice with 400 ml of dilute hydrochloric acid at pH 2, and then dissolved in 80 ml of methanol. It filtered with the filter paper of No. 2. Thereafter, 800 ml of dilute hydrochloric acid having a pH of 2 was added dropwise to the filtrate while stirring, and then cooled again in the refrigerator for 30 minutes.
- the polymer [I] has a molecular weight of less than 10,000, 18% by weight, a molecular weight of 10,000 or more and less than 3,000, 47% by weight and a molecular weight of 30,000 or more and 35% by weight, and an average molecular weight of 21 , 700 and IR, NMR and UV were as follows:
- polymer [lb] This polymer [I] is referred to as “polymer [lb]”.
- solution A and solution B were mixed, and 2.86 liters of solution C was added dropwise over 1 hour with stirring, and then acetic acid was added to adjust the solution to pH3. Then, it concentrated with the rotary evaporator, the obtained solid substance was melt
- the polymer [I] has a molecular weight of 27% by weight less than 10,000, a molecular weight of 10,000 or more and less than 3,000, 54% by weight and a molecular weight of 30,000 or more and 19% by weight, and an average molecular weight of 19 , 20
- the IR, ⁇ -NMR and UV were as follows.
- polymer [Ic] This polymer [I] is referred to as “polymer [Ic]”.
- Table 3 shows the evaluation results. This confirmed that the polymer [la] and the polymer [lb] showed better anti-HIV activity than the natural lignin glycoside.
- the therapeutic agent for HPV disease of the present invention comprises an extract based on lignin and a lignin-like polysaccharide extracted from pine force that is easily and widely available, and a stable industrial process.
- the polymer [I] which can be produced with high purity by the method described above, has newly found excellent medicinal effects, and the anti-HIV drug of the present invention comprising the polymer [I] as a main active ingredient is used for infection. Shows extremely good efficacy against the growing HIV. In particular, the polymer [I] stably exhibits an excellent medicinal effect rather than natural lignin.
- FIG. 1 is a diagram illustrating the flow of hot water extraction and alkaline aqueous solution extraction of pine cones.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006528613A JPWO2006001364A1 (ja) | 2004-06-29 | 2005-06-24 | ヒトパピローマウイルス疾患治療薬および抗ヒト免疫不全ウイルス薬 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004190703 | 2004-06-29 | ||
JP2004-190703 | 2004-06-29 | ||
JP2005-180120 | 2005-06-21 | ||
JP2005180120 | 2005-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006001364A1 true WO2006001364A1 (ja) | 2006-01-05 |
Family
ID=35781814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/011600 WO2006001364A1 (ja) | 2004-06-29 | 2005-06-24 | ヒトパピローマウイルス疾患治療薬および抗ヒト免疫不全ウイルス薬 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006001364A1 (ja) |
WO (1) | WO2006001364A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108042519A (zh) * | 2017-12-21 | 2018-05-18 | 南方医科大学 | 咖啡酸在制备抗hpv病毒感染药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07206601A (ja) * | 1994-01-21 | 1995-08-08 | Lederle Japan Ltd | ウイルス感染防止用添加剤 |
JP2002204687A (ja) * | 2000-11-09 | 2002-07-23 | Onaka Yasushi | β−1.3−1.6グルカン(アウレオバシジウム培養液)の医療、保健、福祉、食品および各種産業分野での応用 |
WO2003026578A2 (en) * | 2001-09-26 | 2003-04-03 | Akiko Tanaka | Pine cone extracts and uses thereof |
JP2004035547A (ja) * | 2002-04-26 | 2004-02-05 | Ethicon Inc | 一定の基質上に薬物物質を堆積するための塗布技法 |
-
2005
- 2005-06-24 JP JP2006528613A patent/JPWO2006001364A1/ja active Pending
- 2005-06-24 WO PCT/JP2005/011600 patent/WO2006001364A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07206601A (ja) * | 1994-01-21 | 1995-08-08 | Lederle Japan Ltd | ウイルス感染防止用添加剤 |
JP2002204687A (ja) * | 2000-11-09 | 2002-07-23 | Onaka Yasushi | β−1.3−1.6グルカン(アウレオバシジウム培養液)の医療、保健、福祉、食品および各種産業分野での応用 |
WO2003026578A2 (en) * | 2001-09-26 | 2003-04-03 | Akiko Tanaka | Pine cone extracts and uses thereof |
JP2004035547A (ja) * | 2002-04-26 | 2004-02-05 | Ethicon Inc | 一定の基質上に薬物物質を堆積するための塗布技法 |
Non-Patent Citations (2)
Title |
---|
EBERHARDT T.L. ET AL: "Assessment of the Anti-HIV Activity of Pine Cone Isolate", PLANTA MED., vol. 62, no. 11, 1996, pages 63 - 65 * |
LAI P.K. ET AL: "Polymeric Phenyl propenoids are the Active Components in the Pine Cone Extract that inhibit the Replication of Type-1 Human Immuno deficiency Virus in vitro", J.GEN.APPL.MICROBIOL., vol. 38, no. 4, 1992, pages 303 - 312 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108042519A (zh) * | 2017-12-21 | 2018-05-18 | 南方医科大学 | 咖啡酸在制备抗hpv病毒感染药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006001364A1 (ja) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5538611B2 (ja) | メイラード反応阻害剤 | |
JPH08500589A (ja) | アストラガルス ポリサッカライド免疫調節剤 | |
JPH06502413A (ja) | 抗ウイルス活性をもつプロアントシアニジンポリマーおよびその製造法 | |
JPS5953883B2 (ja) | 「はん」痕形成剤 | |
JP6656316B2 (ja) | ハマナツメの使用方法、ハマナツメ抽出物の使用方法及び薬物混合物の使用方法 | |
JPH1059846A (ja) | 白内障の予防または治療薬剤 | |
JPS60214741A (ja) | 血糖降下剤 | |
KR20090034401A (ko) | 유칼립투스 추출물, 그 제조 방법 및 치료적 용도 | |
DK172879B1 (da) | Silibininholdigt farmaceutisk præparat | |
AU2003242135A1 (en) | Preparation Method of Danshentotalphenolic Acid and the Use Thereof | |
JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
KR20010082721A (ko) | 지방산 함유 조성물 | |
WO2006001364A1 (ja) | ヒトパピローマウイルス疾患治療薬および抗ヒト免疫不全ウイルス薬 | |
JP2944345B2 (ja) | 抗炎症、抗かゆみ外用剤 | |
JP5086805B2 (ja) | 「抗ガン性野生チョウセンニンジンの精製エキス調整法及びそのガン融合製剤」 | |
CN101028437A (zh) | 一种防治心脑血管疾病的中药有效部位组合物及制备方法 | |
JP4979053B2 (ja) | リンドウ抽出物を含む制癌剤、健康補助食品及び薬用化粧品、並びにリンドウ抽出物の製造方法 | |
CN101357212B (zh) | 一种复方斑蝥注射制剂及其制备方法 | |
RU2792613C1 (ru) | Противоопухолевые средства на основе макро- и микроэлементсодержащих полигалактуронатов (варианты) | |
WO2001049293A1 (fr) | Formulation pharmaceutique anti-inflammatoire et anti-exsudative a toxicite reduite | |
JP3958502B2 (ja) | アポトーシスを誘導する新規多糖およびその用途 | |
JP3254567B2 (ja) | 植物組織からの生理活性物質の製造方法及びこの物質を含有する組成物 | |
CN101116713A (zh) | 仙人掌芦荟抗癌胶囊及其制备方法 | |
TWI222357B (en) | Anti-ulcer pharmaceutical composition and the preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006528613 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |